Evidence map›Paper›PMID 40304263›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

High-Throughput Tiling of Essential mRNAs Increases Potency of Antisense Antibiotics.

Giorgia Danti, Linda Popella, Jörg Vogel, Hans M Maric

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. High-Throughput Tiling of Essential mRNAs Increases Potency of Antisense Antibiotics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Giorgia DantiRudolf Virchow Center for Integrative and Translational Bioimaging, University of Würzburg, 97080, Würzburg, Germany.ORCID https://orcid.org/0000-0002-6607-9124
Linda PopellaInstitute for Molecular Infection Biology (IMIB), Faculty of Medicine, University of Würzburg, 97080, Würzburg, Germany.ORCID https://orcid.org/0000-0002-5309-5838
Jörg VogelInstitute for Molecular Infection Biology (IMIB), Faculty of Medicine, University of Würzburg, 97080, Würzburg, Germany.ORCID https://orcid.org/0000-0003-2220-1404
Hans M MaricRudolf Virchow Center for Integrative and Translational Bioimaging, University of Würzburg, 97080, Würzburg, Germany.ORCID https://orcid.org/0000-0002-2719-4752

Funding

BMBF Cluster4Future Program Cluster for Nucleic Acid Therapeutics Munich 03ZU1201CADeutsche Forschungsgemeinschaft MA6957/2-1Deutsche Forschungsgemeinschaft Vo875/18
6 · The paper itself

Abstract

Antimicrobial resistance is outpacing drug discovery, creating an urgent need for precision-based strategies to counteract resistant pathogens. Peptide nucleic acid (PNA)-based antisense molecules offer a promising approach by selectively inhibiting essential bacterial mRNAs, but their design rules for optimal efficacy remain incompletely understood. Here, a scalable high-throughput platform is developed for the nanomolar-scale one-shot synthesis of PNAs as carrier peptide conjugates (PPNAs). Parallel synthesis of up to 1,536 PPNAs composed of up to 21 PNA or peptide building blocks enabled systematic, base-by-base analysis of RNA hybridization, mRNA inhibition, and antimicrobial activity across nine essential genes in uropathogenic Escherichia coli. The accuracy and robustness of this high-throughput tiling platform are demonstrated through in-depth analysis of the acpP mRNA and identify potent antisense inhibitors of rpsH, ftsZ, and murA. This approach provides an efficient and scalable route to design and optimize PNA-based antimicrobials, facilitating empirical testing across diverse bacterial targets. By enabling large-scale exploration of the relevant mRNA sequence space, the sequence tiling platform accelerates the discovery of antisense-based antimicrobials, offering a scalable strategy to develop precision therapies against various pathogens and combat resistance.

Indexed as

Anti-Bacterial AgentsPeptide Nucleic AcidsRNA, MessengerHigh-Throughput Screening AssaysMicrobial Sensitivity TestsUropathogenic Escherichia coliAnti-Bacterial AgentsPeptide Nucleic AcidsRNA, MessengeracpPAntisense AntibioticsAsobioticsftsZmRNAmurAPNArpsH

Identifiers

PMID40304263
PMCPMC12302540

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.